Biomarker · Gene alteration

TP53 mutation

Somatic TP53 mutations detected by sequencing of tumor tissue or marrow; used mainly as a prognostic and risk-stratification marker across solid and hematologic malignancies.

CI-BIO-00000034TP53 graph →NCIt C118396

Also calledTP53-mutated · p53 mutation · TP53-mutant

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Neoplasm	21	21	—	—	0 / 1 / 0 / 19 / 1
Malignant Breast Neoplasm	15	5	10	—	0 / 11 / 1 / 2 / 1
Chronic Lymphocytic Leukemia	7	1	6	—	1 / 6 / 0 / 0 / 0
Malignant Ovarian Neoplasm	7	4	3	—	0 / 5 / 2 / 0 / 0
Gastric Carcinoma

Derived

Drugs with predictive evidence (24)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
MDM2 Inhibitor AMGMDS3	17	1	16	D	1 / 16	Malignant Neoplasm
CisplatinSmall Molecule	9	4	5	B	3 / 5	Gastric Carcinoma, Malignant Gastric Neoplasm,

Curated evidence

Predictive evidence items (52)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 52 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 Mutation8
Alemtuzumab

Regulatory

Approvals mentioning the linked drugs (444)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpd

Clinical trials

Active trials (1,111)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 558 recruiting · 287 active phase 3 · 5,094 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 101–150 of 1,111 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05786924	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies	recruiting	Phase 1 / Phase 2	554	Institut de Recherches Internationales Servier

Literature

Linked publications (58)

Publications linked to the scope gene(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–25 of 58 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
· Blood · 2016 · PMID 26837699 · validated civic_curation pubmed
TP53 mutation and survival in chronic lymphocytic leukemia.
· J Clin Oncol · 2010 · PMID 20697090 · validated civic_curation pubmed
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
· Leukemia · 2015 · PMID 24943832 · validated civic_curation pubmed
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
· J Clin Oncol · 2017 · PMID 28453411

TP53 Wildtype6
Chemotherapy	Esophageal Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID906 Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 … (full text at CIViC) PMID 23515910 · Zhang et al., 2013 · Open in CIViC	civic
RG7112	Leukemia	Predictive	B	Supports Sensitivity Response	3	accepted	EID2965 Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild … (full text at CIViC) PMID 26459177 · Andreeff et al., 2016 · Open in CIViC	civic
Adjuvant Chemotherapy	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID1149 Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) vers… (full text at CIViC) PMID 26899019 · Ma et al., 2016 · Open in CIViC	civic
Capecitabine + Cetuximab + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID875 In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; h… (full text at CIViC) PMID 24957073 · Sclafani et al., 2014 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID2964 MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor. PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
Rebemadlin	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID2963 MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. Cells lacking functional T… (full text at CIViC) PMID 17671205 · Efeyan et al., 2007 · Open in CIViC	civic

TP53 R273C2
Cisplatin + Etoposide + MitomycinCombination	Gastric CarcinomaALIAS	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID2292 A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score w… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID4881 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

TP53 Y220C2
Cisplatin + Etoposide + MitomycinCombination	Gastric CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID2306 A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric … (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID4884 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

TP53 R175H4
EAP Protocol	Gastric CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	—	accepted	EID2310 In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
Doxorubicin	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID319 Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53. PMID 22698404 · Jackson et al., 2012 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID4880 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID10074 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

TP53 Deleterious Mutation4
RG7112	Leukemia	Predictive	B	Supports Resistance	3	accepted	EID2966 Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type… (full text at CIViC) PMID 26459177 · Andreeff et al., 2016 · Open in CIViC	civic
Adjuvant Chemotherapy	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1148 Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with TP53wt … (full text at CIViC) PMID 26899019 · Ma et al., 2016 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID2967 MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while th… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
Rebemadlin	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID2968 MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. TP53 mutant cells lacking … (full text at CIViC) PMID 17671205 · Efeyan et al., 2007 · Open in CIViC	civic

TP53 Overexpression2
Cisplatin + Etoposide + MitomycinCombination	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID2799 In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater t… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Malignant Ovarian Neoplasm	Predictive	B	Supports Resistance	3	accepted	EID3013 In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant/r… (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION, MYLAN STD. (DIN 02396890) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 6, 2016	Jun 12, 2013	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION, BP (DIN 02355183) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 10, 2012	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION BP (DIN 02366711) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 25, 2022	Sep 29, 2011	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION BP (DIN 02126613) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 9, 1997	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as PLATINOL AQ INJ 1MG/ML (DIN 00788740) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 30, 2001	Dec 31, 1988	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJ 1MG/ML (DIN 00692743) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 13, 1998	Dec 31, 1986	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJ 0.5MG/ML (DIN 00644293) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1985	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02393832) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02422034) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as PMS-CISPLATIN (DIN 02409194) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Aug 3, 2017	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02409186) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02458020) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 17, 2017	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02439336) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 2, 2016	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02437031) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Oct 29, 2025	Feb 27, 2015	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02412225) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 17, 2018	Mar 28, 2014	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02412233) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 17, 2018	Mar 28, 2014	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION USP (DIN 02361957) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 1, 2011	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177099) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 30, 2018	Dec 31, 1995	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177080) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 31, 2020	Dec 31, 1995	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465647) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02441845) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02444410) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465655) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as PMS-DOCETAXEL (DIN 02436361) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 15, 2023	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as PMS-DOCETAXEL (DIN 02436388) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 15, 2023	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465531) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as TARO-DOXORUBICIN LIPOSOMAL (DIN 02493020) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 19, 2020	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HYDROCHLORIDE INJECTION (DIN 02375710) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 21, 2021	Apr 10, 2015	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HYDROCHLORIDE INJECTION, USP (DIN 02413973) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jun 1, 2021	Jan 8, 2015	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN INJECTION, BP (DIN 02381982) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 16, 2014	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN (DIN 02410397) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 21, 2014	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HYDROCHLORIDE INJECTION (DIN 02409275) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 27, 2014	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as MYOCET (DIN 02245015) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Sep 7, 2018	Dec 21, 2001	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as CAELYX (DIN 02238389) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 19, 1998	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP (DIN 02194457) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince May 9, 2024	Mar 12, 1998	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HYDROCHLORIDE INJECTION (DIN 02230108) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 2, 2018	Sep 12, 1997	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP (DIN 02194465) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 30, 1997	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP (DIN 02194473) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 8, 1997	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as ADRIAMYCIN RDF (DIN 02065657) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 2, 2006	Dec 31, 1996	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as ADRIAMYCIN RDF (DIN 02069563) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 2, 2006	Dec 31, 1996	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HCL FOR INJ. U.S.P. 150MG/VIAL (DIN 02093081) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 14, 1997	Dec 31, 1995	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HCL FOR INJ. U.S.P. 50MG/VIAL (DIN 02093073) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 14, 1997	Dec 31, 1995	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL (DIN 02093057) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 13, 1998	Dec 31, 1995	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as ADRIAMYCIN RDF (DIN 02069555) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 2, 2006	Dec 31, 1995	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as ADRIAMYCIN PFS (DIN 02071002) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Aug 2, 2017	Dec 31, 1995	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as ADRIAMYCIN RDF INJ 150MG/VIAL (DIN 00768766) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1988	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as ADRIAMYCIN RDF INJ 10MG/VIAL (DIN 00357391) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1976	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as ADRIAMYCIN RDF INJ 50MG/VIAL (DIN 00353078) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1976	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP (DIN 02467240) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 14, 2026	—	health-canada-dpd
Doxorubicin	CA Health Canada	—	Marketed in Canada as PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE FOR INJECTION (DIN 02544857) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd